Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2026)
Agios Pharmaceuticals (AGIO) reported Gross Margin of 93.64% for Q1 2026, up 608.0% on a YoY basis from 13.23% in Q1 2025, and up 3.37% quarter-over-quarter from 90.59% in Q4 2025.
Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported Gross Margin for 9 years, with the latest figure at 93.64% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 608.0% year-over-year to 93.64%; the trailing twelve-month figure through Mar 2026 stood at 90.04% (up 252.0% YoY), and the FY2025 full-year result was 88.26%, down 33.0% from the prior year.
- Gross Margin for Q1 2026 stood at 93.64%, up from 90.59% in the prior quarter.
- The five-year high for Gross Margin was 93.64% in Q1 2026, with the low at 59.25% in Q1 2022.
- Historically, Gross Margin has averaged 87.27% across 5 years, with a median of 90.12% in 2023.
- The largest YoY upside for Gross Margin was 3087 bps in 2023 against a maximum downside of 871 bps in 2023.
- Agios Pharmaceuticals' Gross Margin stood at 90.42% in 2022, then gained by 1 bps to 91.75% in 2023, then fell by 4 bps to 88.26% in 2024, then gained by 3 bps to 90.59% in 2025, then gained by 3 bps to 93.64% in 2026.
- The last three Gross Margin figures came in at 93.64% (Q1 2026), 90.59% (Q4 2025), and 86.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | 93.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.64% |
| Dec 31, 2025 | 90.59% |
| Sep 30, 2025 | 86.96% |
| Jun 30, 2025 | 86.33% |
| Mar 31, 2025 | 87.57% |
| Dec 31, 2024 | 88.26% |
| Sep 30, 2024 | 91.27% |
| Jun 30, 2024 | 82.65% |
| Mar 31, 2024 | 92.34% |
| Dec 31, 2023 | 91.75% |
| Sep 30, 2023 | 91.44% |
| Jun 30, 2023 | 83.49% |
| Mar 31, 2023 | 90.12% |
| Dec 31, 2022 | 90.42% |
| Sep 30, 2022 | 85.30% |
| Jun 30, 2022 | 92.21% |
| Mar 31, 2022 | 59.25% |
| Dec 31, 2020 | 104.19% |
| Sep 30, 2020 | 98.16% |
| Jun 30, 2020 | 98.19% |